Pembrolizumab blood level monitoring for NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This study checks how well pembrolizumab (Keytruda) works in people with non-small cell lung cancer (NSCLC) by measuring the drug levels in your blood. It aims to see if adjusting the dose based on these levels improves treatment and reduces side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You have non-small cell lung cancer (NSCLC).
- You are being treated with pembrolizumab (Keytruda), either alone or with other drugs.
- You have a working IV line (like a peripheral IV, PICC line, or port) for your treatment.
- You agree to take part in the study and are not under any legal guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial is testing whether a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) is effective for people with advanced non-small cell lung cancer. If you haven't had treatment yet and meet the health criteria, this study could offer a new option to control your cancer.
This study is testing whether the immunotherapy drug pembrolizumab (Keytruda) works better for people with advanced non-small cell lung cancer by looking at their immune system's T-cells (a type of white blood cell). The goal is to understand which patients benefit most, which could help guide more personalized treatment.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.